CoChat

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets

Open access

The DOI matches its Crossref record; 48 of the 50 references it cites were found in a registry or an index.

Abstract

The incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) mediate insulin responses that are proportionate to nutrient intake to facilitate glucose tolerance 1 . The GLP-1 receptor (GLP-1R) is an established drug target for the treatment of diabetes and obesity 2 , whereas the therapeutic potential of the GIP receptor (GIPR) is a subject of debate. Tirzepatide is an agonist at both the GIPR and GLP-1R and is a highly effective treatment for type 2 diabetes and obesity 3,4 . However, although tirzepatide activates GIPR in cell lines and mouse models, it is not clear whether or how dual agonism contributes to its therapeutic benefit. Islet beta cells express both the GLP-1R and the GIPR, and insulin secretion is an established mechanism by which incretin agonists improve glycemic control 5 . Here, we show that in mouse islets, tirzepatide stimulates insulin secretion predominantly through the GLP-1R, owing to reduced potency at the mouse GIPR. However, in human islets, antagonizing GIPR activity consistently decreases the insulin response to tirzepatide. Moreover, tirzepatide enhances glucagon secretion and somatostatin secretion in human islets. These data demonstrate that tirzepatide stimulates islet hormone secretion from human islets through both incretin receptors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42255-023-00811-0

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Tirzepatide stimulates insulin secretion in mice predominantly through the GLP-1R. a, Mouse islets from control mice and mice with beta-cell-specific deletion of the Gipr (Gipr-β-cell-/-) were perifused with ramping concentrations of tirzepatide (TZP) (0–100 nM) with or without Ex9 at a 1 μM concentration beginning at minute 28. The iAUC was calculated for TZP using the value at minute 42 as the baseline. n = 5 for all groups. b, Mouse islets were perifused with increasing concentrations of TZP (0–100 nM) in the presence of Ex9, a GIPR antagonist (GIPR ant) or a combination of both. All antagonists were used at 1 μM concentrations starting at minute 28. The iAUC was calculated for TZP using the value at minute 42 as the baseline. PBS and GIPR ant, n = 4; Ex9 and Ex9 + GIPR ant, n = 5. c, Glycemia after a 5 h fast, immediately before the administration of glucose. Antagonists were administered 2 h before and TZP was administered 1 h before. n = 8 for all groups. d, Glycemia during the IPGTT. The iAUC was calculated using the fasting glycemia value. PBS, TZP and TZP + GIPR ant, n = 8; TZP + GLP-1R ant and TZP + GLP-1R/GIPR ant, n = 7. All values are mean ± s.e.m. Statistical tests were two-way ANOVA with Tukey’s post-hoc test (a) and one-way ANOVA with Tukey’s post-hoc test (b–d). Source data
Fig. 1 Tirzepatide stimulates insulin secretion in mice predominantly through the GLP-1R. a, Mouse islets from control mice and mice with beta-cell-specific deletion of the Gipr (Gipr-β-cell-/-) were perifused with ramping concentrations of tirzepatide (TZP) (0–100 nM) with or without Ex9 at a 1 μM concentration beginning at minute 28. The iAUC was calculated for TZP using the value at minute 42 as the baseline. n = 5 for all groups. b, Mouse islets were perifused with increasing concentrations of TZP (0–100 nM) in the presence of Ex9, a GIPR antagonist (GIPR ant) or a combination of both. All antagonists were used at 1 μM concentrations starting at minute 28. The iAUC was calculated for TZP using the value at minute 42 as the baseline. PBS and GIPR ant, n = 4; Ex9 and Ex9 + GIPR ant, n = 5. c, Glycemia after a 5 h fast, immediately before the administration of glucose. Antagonists were administered 2 h before and TZP was administered 1 h before. n = 8 for all groups. d, Glycemia during the IPGTT. The iAUC was calculated using the fasting glycemia value. PBS, TZP and TZP + GIPR ant, n = 8; TZP + GLP-1R ant and TZP + GLP-1R/GIPR ant, n = 7. All values are mean ± s.e.m. Statistical tests were two-way ANOVA with Tukey’s post-hoc test (a) and one-way ANOVA with Tukey’s post-hoc test (b–d). Source dataCC BY · PubMed Central
Fig. 2 Tirzepatide stimulates insulin secretion through both the GLP-1R and GIPR in human islets. a, Islet perifusion from one set of human islets. Insulin secretion was measured in response to 30 nM tirzepatide in the presence of Ex9 (1 μM), a GIPR antagonist (GIPR ant) or both. n = 3 per group. b, iAUC values for insulin secretion in response to tirzepatide in eight individual sets of human islets. The dashed line indicates the level of glucose-stimulated insulin secretion before tirzepatide stimulation. n = 3 per group. c, Summary data of all eight experiments in human islets. Each individual experiment was averaged to produce a single data point for each condition and expressed as a relative value to control conditions. Individual experiments have connecting lines. n = 8. All values are mean ± s.e.m. The statistical test was one-way ANOVA with Tukey’s post-hoc test (b,c). Source data
Fig. 2 Tirzepatide stimulates insulin secretion through both the GLP-1R and GIPR in human islets. a, Islet perifusion from one set of human islets. Insulin secretion was measured in response to 30 nM tirzepatide in the presence of Ex9 (1 μM), a GIPR antagonist (GIPR ant) or both. n = 3 per group. b, iAUC values for insulin secretion in response to tirzepatide in eight individual sets of human islets. The dashed line indicates the level of glucose-stimulated insulin secretion before tirzepatide stimulation. n = 3 per group. c, Summary data of all eight experiments in human islets. Each individual experiment was averaged to produce a single data point for each condition and expressed as a relative value to control conditions. Individual experiments have connecting lines. n = 8. All values are mean ± s.e.m. The statistical test was one-way ANOVA with Tukey’s post-hoc test (b,c). Source dataCC BY · PubMed Central
Fig. 3 Tirzepatide stimulates glucagon secretion in human islets. a, Glucagon secretion from human islets stimulated with either 30 nM hGIP or GLP-1 individually (minutes 8–24) or together (minutes 32–50) under 16 mM glucose conditions. The iAUC was calculated for the individual effects of the peptides (minutes 8–24) and the combined effects (minutes 32–50) using the value of the first time point as the baseline. GIP, n = 4; GLP-1, n = 6; GIP + GLP-1, n = 10. b, Glucagon secretion from human islets treated with 30 nM of either hGIP or tirzepatide (TZP) under 16 mM glucose conditions. The iAUC was calculated using minutes 24 and 54 as the baseline values for the first and second stimulation, respectively. n = 3 for all groups. c, Glucagon secretion in response to 30 nM TZP in eight individual donor sets of human islets under 16 mM glucose conditions. The summary of these experiments is shown as the of the average values from minutes 55–65. The fold induction on the right y axis was calculated using the baseline glucagon values from minutes 35–45. n = 3 for each donor, n = 8 for summary data. d, Glucagon secretion in human islets (donor R464) stimulated with TZP (30 nM) at either 2.7 mM glucose (2.7 G) or 10 mM glucose (10 G), with or without 3 mM alanine. n = 3. e, Somatostatin concentrations from pooled samples taken from baseline samples or during TZP stimulation. n = 3. All values are mean ± s.e.m. Statistical tests were one-way ANOVA with Tukey’s post-hoc test (a), two-way ANOVA with Sidak post-hoc test (b), paired t-test (c,d) and unpaired t-test (e). Source data
Fig. 3 Tirzepatide stimulates glucagon secretion in human islets. a, Glucagon secretion from human islets stimulated with either 30 nM hGIP or GLP-1 individually (minutes 8–24) or together (minutes 32–50) under 16 mM glucose conditions. The iAUC was calculated for the individual effects of the peptides (minutes 8–24) and the combined effects (minutes 32–50) using the value of the first time point as the baseline. GIP, n = 4; GLP-1, n = 6; GIP + GLP-1, n = 10. b, Glucagon secretion from human islets treated with 30 nM of either hGIP or tirzepatide (TZP) under 16 mM glucose conditions. The iAUC was calculated using minutes 24 and 54 as the baseline values for the first and second stimulation, respectively. n = 3 for all groups. c, Glucagon secretion in response to 30 nM TZP in eight individual donor sets of human islets under 16 mM glucose conditions. The summary of these experiments is shown as the of the average values from minutes 55–65. The fold induction on the right y axis was calculated using the baseline glucagon values from minutes 35–45. n = 3 for each donor, n = 8 for summary data. d, Glucagon secretion in human islets (donor R464) stimulated with TZP (30 nM) at either 2.7 mM glucose (2.7 G) or 10 mM glucose (10 G), with or without 3 mM alanine. n = 3. e, Somatostatin concentrations from pooled samples taken from baseline samples or during TZP stimulation. n = 3. All values are mean ± s.e.m. Statistical tests were one-way ANOVA with Tukey’s post-hoc test (a), two-way ANOVA with Sidak post-hoc test (b), paired t-test (c,d) and unpaired t-test (e). Source dataCC BY · PubMed Central
Extended Data Fig. 1 Tirzepatide activity in mice. A) Intraperitoneal glucose tolerance test (IPGTT) in wild-type (WT) mice. Mice were pretreated 2 hours prior to glucose with either PBS or a GIPR antagonist, 1 hour prior to glucose with either PBS or acyl-GIP (3 or 10 nmol/kg dose). Glucose was given after a 5 hour fast at 1.5 mg/kg. The integrated area under the curve (iAUC) was calculated using the glycemia measure immediately before PBS/GIPR antagonist administration. 3 nmol/kg dose: PBS/PBS, n = 7; PBS/Acyl-GIP, n = 6, GIPR Antag/Acyl-GIP, n = 6. 10 nmol/kg dose: PBS/PBS, n = 7; PBS/Acyl-GIP, n = 8, GIPR Antag/Acyl-GIP, n = 7. B) A dose-response curve for tirzepatide during an IPGTT in WT mice. (n = 5/group) B) Tirzepatide during an IPGTT in WT and Glp1r knockout mice. (n = 8/group) C) 30 nmol/kg tirzepatide in WT mice treated with an antagonist for the GLP-1R (Jant-4), GIPR, or both. N = 8/group. All values are mean + /- SEM. The following statistical tests were used: A, B, and D) one-way ANOVA with Tukey’s posthoc test, C) two-way ANOVA with Tukey’s posthoc test. Source data
Extended Data Fig. 1 Tirzepatide activity in mice. A) Intraperitoneal glucose tolerance test (IPGTT) in wild-type (WT) mice. Mice were pretreated 2 hours prior to glucose with either PBS or a GIPR antagonist, 1 hour prior to glucose with either PBS or acyl-GIP (3 or 10 nmol/kg dose). Glucose was given after a 5 hour fast at 1.5 mg/kg. The integrated area under the curve (iAUC) was calculated using the glycemia measure immediately before PBS/GIPR antagonist administration. 3 nmol/kg dose: PBS/PBS, n = 7; PBS/Acyl-GIP, n = 6, GIPR Antag/Acyl-GIP, n = 6. 10 nmol/kg dose: PBS/PBS, n = 7; PBS/Acyl-GIP, n = 8, GIPR Antag/Acyl-GIP, n = 7. B) A dose-response curve for tirzepatide during an IPGTT in WT mice. (n = 5/group) B) Tirzepatide during an IPGTT in WT and Glp1r knockout mice. (n = 8/group) C) 30 nmol/kg tirzepatide in WT mice treated with an antagonist for the GLP-1R (Jant-4), GIPR, or both. N = 8/group. All values are mean + /- SEM. The following statistical tests were used: A, B, and D) one-way ANOVA with Tukey’s posthoc test, C) two-way ANOVA with Tukey’s posthoc test. Source dataCC BY · PubMed Central
Extended Data Fig. 2 Tirzepatide stimulated insulin secretion in human islets. Two independent donor sets of human islets were stimulated with 30 nM tirzepatide (TZP) in the presence of 1μM concentrations of exendin(9-39) (Ex9), hGIP(3-30) (GIPR Ant) or the combination. The integrated area under the curve (iAUC) was calculated for both glucose and tirzepatide stimulated insulin secretion using the value of the first time point as the baseline. All values are mean + /- SEM, n = 3/group. A one-way ANOVA with Tukey’s posthoc test was used. Source data
Extended Data Fig. 2 Tirzepatide stimulated insulin secretion in human islets. Two independent donor sets of human islets were stimulated with 30 nM tirzepatide (TZP) in the presence of 1μM concentrations of exendin(9-39) (Ex9), hGIP(3-30) (GIPR Ant) or the combination. The integrated area under the curve (iAUC) was calculated for both glucose and tirzepatide stimulated insulin secretion using the value of the first time point as the baseline. All values are mean + /- SEM, n = 3/group. A one-way ANOVA with Tukey’s posthoc test was used. Source dataCC BY · PubMed Central
Extended Data Fig. 3 GIPR but not GLP-1R is needed for tirzepatide-stimulated glucagon secretion. Human islets were stimulated with either tirzepatide or hGIP in the presence of the GIPR antagonist (GIPR Ant – left panel) or exendin(9-39) (Ex9 – right). Tirzepatide was used at 30 nM and the antagonists were used at 1μM concentrations. All values are mean + /- SEM, n = 3/group for GIPR antagonist and 6/group for Ex9. A two-way ANOVA with Tukey’s posthoc test was used. Source data
Extended Data Fig. 3 GIPR but not GLP-1R is needed for tirzepatide-stimulated glucagon secretion. Human islets were stimulated with either tirzepatide or hGIP in the presence of the GIPR antagonist (GIPR Ant – left panel) or exendin(9-39) (Ex9 – right). Tirzepatide was used at 30 nM and the antagonists were used at 1μM concentrations. All values are mean + /- SEM, n = 3/group for GIPR antagonist and 6/group for Ex9. A two-way ANOVA with Tukey’s posthoc test was used. Source dataCC BY · PubMed Central
Extended Data Fig. 4 GIP and amino acids synergistically increase glucose secretion in human islets. Human islets were treated with 30 nM hGIP or 3 mM amino acids (combination of glutamine, arginine, alanine, and leucine), individually or in combination. All values are mean ± SEM, n = 3/group. A two-way ANOVA with Tukey’s posthoc test was used. Source data
Extended Data Fig. 4 GIP and amino acids synergistically increase glucose secretion in human islets. Human islets were treated with 30 nM hGIP or 3 mM amino acids (combination of glutamine, arginine, alanine, and leucine), individually or in combination. All values are mean ± SEM, n = 3/group. A two-way ANOVA with Tukey’s posthoc test was used. Source dataCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 1

  1. Sparre-Ulrich, A. H. et al. GIP(3-30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release. Biochem. Pharmacol. 131, 78–88 (2017). · DOI · Paper page

Cited by

See all 120

Metadata

Authors
El, K., Douros, J. D., Willard, F. S., Novikoff, A., Sargsyan, A., Perez-Tilve, D., Wainscott, D. B., Yang, B., Chen, A., Wothe, D., Coupland, C., Tschöp, M. H., Finan, B., D’Alessio, D. A., Sloop, K. W., Müller, T. D., & Campbell, J. E.
Affiliations
  • Duke University (US)
  • Eli Lilly (United States) (US)
  • Helmholtz Munich (DE)
Corresponding author
  • Sloop, Kyle W.
  • Müller, Timo D.
  • Campbell, Jonathan E.
Venue
Nature Metabolism
Published
2023-06-05
Volume
5
Issue
6
Pages
945-954
ISSN
2522-5812 (ISSN-L)
OpenAlex
W4379471679
Cited by
118
References
50
Citations by year
2026: 23 · 2025: 42 · 2024: 38 · 2023: 15
FWCI
32.04
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Metabolism (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders
  • Eli Lilly and Company
  • Leona M. and Harry B. Helmsley Charitable Trust
  • Deutsche Forschungsgemeinschaft (DFG-TRR296, GRK2816/1, TRR- 152, SFB1123, TRR296, TRR152, TRR296)
  • Novo Nordisk
  • National Institutes of Health (DK046492)
  • Helmholtz Zentrum München
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK125353, DK123075, R01DK123075, R37DK046492, DK125353, DK046492, R01DK046492, T32DK007012, K01DK132461)
  • H2020 European Research Council (695054)
  • HORIZON EUROPE European Research Council (101044445)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
tirzepatide, GIP receptor, GLP-1 receptor, insulin secretion, human pancreatic islets, glucagon secretion, somatostatin secretion, type 2 diabetes, obesity, incretin signaling
MeSH terms
Glucagon-Like Peptide Receptors, Tirzepatide, Animals, Cells, Cultured, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Insulin, Islets of Langerhans, Mice, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. https://app.cochat.ai/papers/10.1038/s42255-023-00811-0
The paper
El, K., Douros, J. D., Willard, F. S., Novikoff, A., Sargsyan, A., Perez-Tilve, D., Wainscott, D. B., Yang, B., Chen, A., Wothe, D., Coupland, C., Tschöp, M. H., Finan, B., D’Alessio, D. A., Sloop, K. W., Müller, T. D., & Campbell, J. E. (2023). The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nature Metabolism. https://doi.org/10.1038/s42255-023-00811-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.